{
  "ticker": "NOX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969617",
  "id": "02969617",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250716",
  "time": "0814",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250716/pdf/06ltymb1978j9t.pdf",
  "summary": "- **First SOF-SKN\u2122 dose administered** in the HERACLES clinical trial (first-in-human study).  \n- **Trial focus**: Safety, tolerability, and dose-finding across four ascending dose cohorts.  \n- **Target market**: Lupus (global market >US$3 billion), with potential expansion to psoriasis, atopic dermatitis, and other autoimmune diseases.  \n- **No financial or capital markets-related data** (e.g., fundraising, cash balance, or material commercial agreements) disclosed.  \n\n*Summary: Clinical milestone update only\u2014no immediate trading or capital markets impact.*",
  "usage": {
    "prompt_tokens": 1316,
    "completion_tokens": 123,
    "total_tokens": 1439,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-15T22:18:46.179878"
}